Literature DB >> 18317945

Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells.

David Nikoleishvili1, Ambrosi Pertia, Omar Trsintsadze, Nino Gogokhia, Laurent Managadze, Archil Chkhotua.   

Abstract

p27((Kip1)), cyclin D3 and Ki67 are the markers of DNA damage and cell proliferation. The goal of the current study was to analyze expression of the markers in benign and malignant prostate cancer tissues. Activity of p27((Kip1)), cyclin D3 and Ki67 was immunohistochemically evaluated in different cells of BPH, prostate cancer (PCa) and hormonally treated prostate cancer (HTPCa) tissues. The tissue samples were derived by means of TURP or radical prostatectomy. Intensity of the expression was compared between the groups, and association was sought with clinical parameters. Total expression of p27((Kip1)) was significantly higher in BPH as compared with PCa. Epithelial marker expression was higher in HTPCa than in PCa. Intensity of the expression in epithelial, vascular and ductal cells was negatively associated with the tumor stage and Gleason grades. Total Ki67 activity was positively correlated with patient age and serum PSA level. There was significantly higher expression in PCa and hormone-escaped PCa (HEPCa) as compared with BPH. Epithelial and vascular marker expression was positively associated with tumor stage and Gleason grades. There was a positive correlation between cyclin D3 and serum PSA level. With the increase of Gleason grades, cyclin D3 expression increased significantly. Expression of p27((Kip1)) negatively correlated with Ki67 and cyclin D3, while the latter two markers correlated positively. p27((Kip1)) is down-regulated, whereas Ki67 and cyclin D3 are up-regulated in PCa. Intensity of the markers' expression is associated with tumor stage and grades. Hormonotherapy of PCa causes activation of p27((Kip1)). HEPCa is characterized by increased Ki67 expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317945     DOI: 10.1007/s11255-008-9350-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  17 in total

1.  The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.

Authors:  L Cheng; R V Lloyd; A L Weaver; T M Pisansky; J C Cheville; D M Ramnani; B C Leibovich; M L Blute; H Zincke; D G Bostwick
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

2.  Cyclin A and Ki-67 with DNA content in benign and malignant prostatic epithelial lesions.

Authors:  T Mirtti; M Kallajoki; M Aaltonen; K Alanen
Journal:  Anal Quant Cytol Histol       Date:  2001-06       Impact factor: 0.302

3.  Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy.

Authors:  Stephen J Freedland; Frank deGregorio; John C Sacoolidge; Yahya I Elshimali; George S Csathy; Frederick Dorey; Robert E Reiter; William J Aronson
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

4.  Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor.

Authors:  Marine Faussillon; Lucie Monnier; Claudine Junien; Cécile Jeanpierre
Journal:  Cancer Lett       Date:  2005-04-18       Impact factor: 8.679

5.  Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.

Authors:  Takahiro Inoue; Takehiko Segawa; Taizou Shiraishi; Toru Yoshida; Yoshinobu Toda; Tomomi Yamada; Naoko Kinukawa; Hidefumi Kinoshita; Toshiyuki Kamoto; Osamu Ogawa
Journal:  Urology       Date:  2005-08       Impact factor: 2.649

6.  Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage.

Authors:  G V Thomas; M I Schrage; L Rosenfelt; J H Kim; G Salur; J B deKernion; F Dorey; J Said; R E Reiter
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

7.  Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies.

Authors:  Tina Dreher; Hanswalter Zentgraf; Ulrich Abel; Alexandra Kappeler; Maurice S Michel; Uwe Bleyl; Rainer Grobholz
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

8.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites.

Authors:  Chistopher K Poulos; Joanne K Daggy; Liang Cheng
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

10.  Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients.

Authors:  M Kuczyk; S Machtens; K Hradil; J Schubach; W Christian; R Knüchel; J Hartmann; C Bokemeyer; U Jonas; J Serth
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

View more
  9 in total

1.  Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines.

Authors:  Canan Eroğlu; Mücahit Seçme; Gülseren Bağcı; Yavuz Dodurga
Journal:  Tumour Biol       Date:  2015-06-30

Review 2.  The AR dependent cell cycle: mechanisms and cancer relevance.

Authors:  Matthew J Schiewer; Michael A Augello; Karen E Knudsen
Journal:  Mol Cell Endocrinol       Date:  2011-07-12       Impact factor: 4.102

3.  Changes of protein expression in prostate cancer having lost its androgen sensitivity.

Authors:  Gergely Bánfi; Ivett Teleki; Péter Nyirády; Attila Keszthelyi; Imre Romics; Attila Fintha; Tibor Krenács; Béla Szende
Journal:  Int Urol Nephrol       Date:  2015-05-08       Impact factor: 2.370

4.  Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer.

Authors:  Panagiotis J Vlachostergios; Foteini Karasavvidou; Grigorios Kakkas; Kassiani Kapatou; Ioannis Gioulbasanis; Danai D Daliani; George Moutzouris; Christos N Papandreou
Journal:  J Negat Results Biomed       Date:  2012-01-05

5.  Significance of p53 and ki-67 expression in prostate cancer.

Authors:  Renuka Verma; Veena Gupta; Jagjeet Singh; Monica Verma; Gopal Gupta; Sumiti Gupta; Rajeev Sen; Megha Ralli
Journal:  Urol Ann       Date:  2015 Oct-Dec

6.  Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis.

Authors:  Cristina-Anita Ionescu; Mariana Aschie; Elena Matei; Georgeta Camelia Cozaru; Mariana Deacu; Anca Florentina Mitroi; Gabriela Isabela Baltatescu; Antonela-Anca Nicolau; Laura Mazilu; Liliana Ana Tuta; Ionut Ciprian Iorga; Alina Stanigut; Manuela Enciu
Journal:  Biomedicines       Date:  2022-07-12

Review 7.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553

Review 8.  Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts.

Authors:  Akhilesh Prajapati; Sharad Gupta; Bhavesh Mistry; Sarita Gupta
Journal:  Biomed Res Int       Date:  2013-07-08       Impact factor: 3.411

9.  Prostatic metastasis from intrahepatic cholangiocarcinoma.

Authors:  Georgi Tosev; Viktoria Schuetz; Joanne Nyarangi-Dix; Albrecht Stenzinger; Fabian Stoegbauer; Yakup Kulu; Jan P Radtke; Dogu Teber; Martin Hatzinger; Christoph Springfeld; Bruno C Koehler; Markus Hohenfellner
Journal:  Urol Case Rep       Date:  2018-07-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.